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i.org/1reduced low-density lipoprotein cholesterol (LDL-C) levels in phase 2 and 3 studies. This
phase 3 study evaluated the efﬁcacy and safety of evolocumab plus atorvastatin in Japanese
patients with hyperlipidemia or mixed dyslipidemia and high cardiovascular risk. Patients
were randomized to atorvastatin 5 or 20 mg/day for 4 weeks. Subsequently, patients
underwent second randomization to evolocumab 140 mg biweekly (Q2W) or 420 mg
monthly (QM) or placebo Q2W or QM. Coprimary end points were % change from baseline
in LDL-C at week 12 and mean of weeks 10 and 12. Secondary end points included change
and % change in other lipids and proportion of patients reaching LDL-C <70 mg/dl.
Adverse events and laboratory values were recorded. Four hundred four patients were
randomized to study drug. At baseline, the mean (SD) age was 61 (10) years (placebo) and
62 (11) years (evolocumab); 39% and 40% were women; 14% and 12% had cerebrovascular
or peripheral arterial disease; and 51% and 47% had diabetes. At entry, mean (SD)
calculated LDL-C was 128 (23) mg/dL; after stabilization on atorvastatin 5 and 20 mg/day,
baseline LDL-C levels were 118 (35) and 94 (24) mg/dL, respectively. Mean LDL-C
reductions at week 12 for evolocumab versus placebo ranged from 67% to 76%. No
imbalances were observed in adverse events between treatment groups. Efﬁcacy and safety
for Q2W or QM evolocumab dosing were similar. In conclusion, in high-risk Japanese
patients receiving stable statin therapy, evolocumab markedly reduced LDL-C and was well
tolerated.  2016 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). (Am
J Cardiol 2016;117:40e47)Proprotein convertase subtilisin/kexin type 9 (PCSK9) is
a serine protease involved in the regulation of low-density
lipoprotein (LDL) receptor expression. PCSK9 binds to the
LDL receptor and targets it for destruction, leading to
decreased LDL receptor expression and an increase in
plasma LDL cholesterol (LDL-C).1 Inhibiting PCSK9 with a
monoclonal antibody reduced serum LDL-C levels in pre-
clinical studies.2e4 Evolocumab is a fully human monoclonal
immunoglobulin G2 antibody against PCSK9 that markedly
reduced serum LDL-C levels in phase 2 and 3 studies.5e16 In
the ﬁrst phase 2 study reported of a PCSK9 inhibitor in
patients in Japan, evolocumab plus background statin ther-
apy reduced LDL-C levels by up to 69% from baseline
versus placebo; favorable changes were seen in other lipid
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0.1016/j.amjcard.2015.10.021to 51% versus placebo.7 YUKAWA-2 (Study of LDL-
Cholesterol Reduction Using a Monoclonal PCSK9 Anti-
body in Japanese Patients With Advanced Cardiovascular
Risk; NCT01953328) is the ﬁrst phase 3 and largest clinical
study to date of a PCSK9 inhibitor in Japan. The primary
objective of the study was to evaluate the efﬁcacy of
12 weeks of subcutaneous evolocumab administered
biweekly (Q2W) or monthly (QM) in combination with
atorvastatin in Japanese patients with hyperlipidemia or
mixed dyslipidemia and at high cardiovascular (CV) risk.
Methods
Eligible patients (aged 20 and 85 years) from study
sites in Japan were at high risk for CV events based on
Japan Atherosclerosis Society (JAS) criteria.17 JAS criteria
used for high-risk classiﬁcation can be found in the
Supplementary Data. Patients were required to be on a
stable dose of an approved statin for 4 weeks before LDL-
C screening without need for uptitration; use of any other
lipid-lowering therapy had to be unchanged within 4 weeks
before LDL-C screening. At screening (before randomiza-
tion to study-speciﬁed background statin therapy), fasting
LDL-C level was required to be 100 mg/dl (2.6 mmol/L),
and fasting triglyceride level was required to be 400 mg/dl
(4.5 mmol/L). Key exclusion criteria can be found in the
Supplementary Data. Independent ethics committees at eachwww.ajconline.org
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Figure 1. Patient disposition. Ator ¼ atorvastatin; EvoMab ¼ evolocumab; Pbo ¼ placebo; PO ¼ per oral; QD ¼ daily; SC ¼ subcutaneous; SD ¼ study drug.
Preventive Cardiology/Evolocumab in Japanese Patients 41study site approved the protocol, and all patients provided
written informed consent before initiation of study-speciﬁc
procedures.
Before randomization, all eligible patients underwent a
placebo run-in period (3 placebo injections) to conﬁrm
tolerance of subcutaneous injections. Patients were then
randomized 1:1 to 1 of 2 atorvastatin treatment groups
consistent with low (5 mg/day) and high (20 mg/day) statin
doses used in clinical practice in participating regions. After
successful completion of a 4-week lipid stabilization period,
patients in each atorvastatin dose cohort were further ran-
domized 1:1:1:1 to 1 of 4 treatment groups: placebo Q2W,
placebo QM, evolocumab 140 mg Q2W, or evolocumab
420 mg QM. Patients were randomized to atorvastatin ther-
apy in 3 strata: patients diagnosed with heterozygous familial
hypercholesterolemia (HeFH); patients without HeFH
receiving intensive lipid-lowering therapy (deﬁned according
to local treatment practices as atorvastatin 10 mg/day or
equivalent); and patients without HeFH receiving non-
intensive lipid-lowering therapy. Patients, investigators, and
study site personnel were blinded to treatment.
The co-primary efﬁcacy end points were the mean %
change from baseline in LDL-C at week 12 (end of study) and
the mean % change from baseline in LDL-C at weeks 10 and
12 (time-averaged reduction in LDL-C). Secondary end
points included the mean change from baseline at weeks 10
and 12 and at week 12 in LDL-C; the mean % change from
baseline at weeks 10 and 12 and at week 12 in other lipids,
including apolipoprotein B (ApoB); achievement of LDL-C
<70 mg/dl; and % change from baseline in Lp(a), tri-
glycerides, high-density lipoprotein cholesterol (HDL-C),
and very-low-density lipoprotein cholesterol. When calcu-
lated LDL-C was<40 mg/dl or triglyceride was>400 mg/dl,a value from the same blood sample measured through pre-
parative ultracentrifugation was used, if available.
A sample size of 45 patients in each of the 8 treatment
groups was calculated to provide >90% power to detect the
treatment effect (30% reduction in LDL-C with a common
SD of 30%) of evolocumab compared with placebo. For the
coprimary end points, a repeated measures linear effects
model was used for each atorvastatin dose cohort and dose
frequency to compare the efﬁcacy of evolocumab with
placebo. The repeated measures model included terms for
treatment group, stratiﬁcation factor, scheduled visit, and
interaction of treatment with scheduled visit. No imputation
of missing data was performed for the repeated measures
linear effects model. Analyses for the secondary end points
were adjusted for multiplicity conditional on the primary
end point meeting statistical signiﬁcance. The secondary
end point of LDL-C response at week 12 was analyzed
using the CochraneMantel Haenszel test adjusted by strat-
iﬁcation factor. Safety outcomes included the incidences of
treatment-emergent adverse events (AEs) and serious AEs
(SAEs), treatment-related AEs, AEs leading to discontinu-
ation of investigational product, and laboratory parameters.
AEs were coded using the Medical Dictionary for Regula-
tory Activities, version 17.0, and graded by severity using
the Common Terminology for Adverse Events (CTCAE),
version 4.3. Laboratory analyses were based on CTCAE,
version 4, toxicity criteria.
Results
In total, 507 patients were screened for the study and 409
were randomized to 1 of 2 atorvastatin doses (5 mg/day or
20 mg/day). All patients were able to tolerate the 3 placebo
Table 1
Demographics, baseline risk factors, and lipid parameters
Variable Placebo þ
Atorvastatin
N ¼ 202
Evolocumab
þ Atorvastatin
N ¼ 202
Age (years, mean  SD) 61  10 62  11
Women 79 (39%) 81 (40%)
Coronary artery disease 22 (11%) 30 (15%)
Peripheral arterial disease or
cerebrovascular disease
29 (14%) 25 (12%)
Hypertension 145 (72%) 152 (75%)
Elevated waist circumference 138 (68%) 138 (68%)
Current smoker 52 (26%) 46 (23%)
Heterozygous familial
hypercholesterolemia
11 (5%) 13 (6%)
Simon-Broome 5 (3%) 3 (2%)
Other* 6 (3%) 10 (5%)
Type 2 diabetes mellitus 103 (51%) 94 (47%)
Metabolic syndrome† 57 (28%) 54 (27%)
 2 cardiovascular risk factors 117 (58%) 113 (56%)
LDL-C (mg/dL, mean  SD)z 103  28 109  35
Lipoprotein (a) (nmol/L, median
[Q1, Q3])z
31 (12, 50) 34 (14, 61)
HDL-C (mg/dL,mean  SD)z 58  14 56  14
Triglycerides (mg/dL, median
[Q1, Q3])z
127 (91, 168) 118 (92,155)
Apolipoprotein B (mg/dL,
mean  SD)z
92  20 96  25
PCSK9 (ng/mL, mean [SD]) z 356 (99) 362 (100)
All demographics and baseline risk factors are given as n (%) unless
indicated otherwise.
HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density
lipoprotein cholesterol; PCSK9 ¼ proprotein convertase subtilisin/kexin
type 9; Q1 ¼ ﬁrst quartile; Q3 ¼ third quartile.
* Japanese deﬁnition based on criteria from Harada-Shiba et al 2012
(reference 43).
†Metabolic syndrome was deﬁned as 3 or more risk factors (elevated
waist circumference, elevated systolic blood pressure or diastolic blood
pressure, elevated fasting glucose, elevated triglycerides, and/or low
HDL-C) and without diabetes mellitus.
z Collected after the lipid-stabilization period and before administration
of ﬁrst dose of study drug.
42 The American Journal of Cardiology (www.ajconline.org)injections given to assess tolerability (none failed to enter
the study because of intolerance of placebo injections).
A total of 404 patients successfully completed the 4-week
lipid stabilization period and were subsequently random-
ized and received study drug (Figure 1). The ﬁrst patient
enrolled on October 7, 2013, and the last patient last visit
was June 25, 2014. In general, baseline patient character-
istics were balanced between the placebo and evolocumab
treatment groups (Table 1). To be eligible for participation
in this study, all patients were required to be at high CV risk
based on local guidelines. Patients most often satisﬁed this
criteria by having diabetes, possessing 2 or more CV risk
factors (such as advanced age, hypertension, or smoking
history) or by being a secondary prevention patient. At
baseline, half of patients had a diagnosis of type 2 diabetes
mellitus and one quarter had a diagnosis of metabolic syn-
drome. Twenty-eight percent of placebo-treated and 37% of
evolocumab-treated patients with metabolic syndrome at
baseline had elevated fasting plasma glucose (110 mg/dl).Study eligibility criteria required all patients to have
received stable statin therapy (deﬁned as 4 weeks) at
home. At screening, 100% of patients were on a statin. The
mean (SD) LDL-C level before the initiation of treatment
with study-provided atorvastatin was 128 (23) mg/dl. In
patients randomized to background atorvastatin 5 mg/day,
the mean (SD) baseline LDL-C at the end of the lipid
stabilization period but before study drug administration
was 115 (28) mg/dl in the placebo group and 120 (41) mg/dl
in the evolocumab group. In patients on background ator-
vastatin 20 mg/day, the corresponding values were 91 (23)
mg/dl in the placebo group and 97 (25) mg/dl in the evo-
locumab group.
At week 12, evolocumab reduced LDL-C by 67%
versus placebo in all evolocumab treatment groups, with
mean reductions ranging from 67% to 76% (Table 2;
Figure 2). Reductions in LDL-C at the time-averaged mean
of weeks 10 and 12 were comparable with those observed at
week 12 (data not shown). Efﬁcacy in the 140-mg Q2W and
420-mg QM doses was comparable; reductions were also
comparable between patient subgroups, including age,
gender, body mass index (BMI), type 2 diabetes mellitus,
and metabolic syndrome (Supplementary Figure S1).
The median (ﬁrst quartile, third quartile) achieved
LDL-C level at week 12 for patients receiving evolocumab
plus atorvastatin was 28 (20, 40) mg/dl and for patients
receiving placebo plus atorvastatin was 97 (83, 115) mg/dl.
The 2012 JAS guidelines recommend LDL-C <120 or
<100 mg/dl for patients at high risk or secondary preven-
tion, respectively.17 In patients receiving placebo plus
atorvastatin, 29% on Q2W placebo plus atorvastatin
5 mg/day and 42% on QM placebo plus atorvastatin 5 mg/
day reached an LDL-C <100 mg/day. Most patients
receiving placebo plus atorvastatin 20 mg/day were able to
achieve an LDL-C <100 mg/dl (59% placebo Q2W and
88% placebo QM). Few patients were able to achieve a
more aggressive target LDL-C of <70 mg/dl on placebo
plus atorvastatin therapy (0% placebo Q2W plus atorvas-
tatin 5 mg/day and 4% placebo QM plus atorvastatin
5 mg/day; 20% placebo Q2W plus atorvastatin 20 mg/day
and 20% placebo QM plus atorvastatin 20 mg/day). In
contrast, 100% of patients treated with evolocumab ach-
ieved an LDL-C <100 mg/dl, and almost all achieved an
LDL-C level <70 mg/dl, regardless of atorvastatin dose
(Table 2, Figure 3).
Favorable changes were observed in other lipid param-
eters at week 12 in the evolocumab treatment groups
(Table 2; Figure 4) with results being similar to the time-
averaged mean of weeks 10 and 12 (data not shown).
The changes were comparable between 140-mg Q2W and
420-mg QM doses. Across evolocumab treatment groups,
the mean (SE) treatment differences versus placebo at week
12 ranged from 56% (2%) to 66% (2%) for apolipo-
protein B; 10% (3%) to 17% (3%) for HDL-C; and 40%
(5%) to 53% (6%) for Lp(a).
AEs were comparable between patients receiving placebo
and those receiving evolocumab (Table 3) without notable
differences seen between patients receiving 140-mg Q2W or
420-mg Q2W (data not shown). Patients demonstrated
similar rates of discontinuation and AEs (including injection
site reactions) across all placebo and evolocumab treatment
Table 2
Efﬁcacy at week 12
Variable Evolocumab þ Atorvastatin 5 mg/d Evolocumab þ Atorvastatin 20 mg/d
Q2W
(N ¼ 50)
QM
(N ¼ 50)
Q2W
(N ¼ 51)
QM
(N ¼ 51)
LS mean (SE) treatment difference versus placebo þ atorvastatin
Low-density lipoprotein cholesterol e74.9% (2.7)* e69.9% (2.4)* e75.9% (3.9)* e66.9% (3.0)*
Apolipoprotein B e65.6% (2.4)* e57.2% (2.4)* e60.4% (2.8)* e56.2% (2.4)*
High-density lipoprotein cholesterol 13.5% (3.1)* 15.2% (2.7)* 16.9% (3.1)* 10.2% (2.7)*
Lipoprotein (a) e50.1% (7.6)* e48.8% (5.9)* e52.7% (5.7)* e40.0% (5.3)*
Triglycerides e27.6% (9.5)† e20.0% (5.9)* e17.2% (5.5)† e16.9% (7.2)z
Apolipoprotein A1 7.3% (2.4)† 8.9% (2.2)* 9.1% (2.4)* 8.6% (2.3)*
Achieved low-density lipoprotein cholesterol
Median (Q1, Q3) Achieved LDL-C, mg/dL 26.0 (16.0, 40.0) 36.0 (29.0, 43.0) 24.5 (18.0, 34.0) 26.0 (20.0, 38.0)
Low-density lipoprotein cholesterol < 70 mg/dL, % patientsx 98.0% 96.0% 96.0% 98.0%
LDL-C ¼ low-density lipoprotein cholesterol; LS ¼ least squares; Q1 ¼ ﬁrst quartile; Q2W ¼ biweekly; Q3 ¼ third quartile; QM ¼ monthly.
* p <0.001.
† p <0.01.
z p <0.05.
x At week 12, in patients receiving 5 mg/day atorvastatin, 0% placebo Q2W and 4% placebo QM reached LDL-C < 70; in patients receiving 20 mg/day
atorvastatin, 20% placebo Q2W and 20% placebo QM reached LDL-C < 70.
Placebo  Evolocumab 140 mg Q2W + atorvastatin 5 mg Evolocumab 420 mg QM + atorvastatin 5 mg Evolocumab 140 mg Q2W + atorvastatin 20 mg Evolocumab 420 mg QM + atorvastatin 20 mg 
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Figure 2. Mean % change from baseline to week 12 in calculated LDL-C. Results are shown for patients receiving placebo (purple squares), evolocumab
420 mg QM þ atorvastatin 5 mg (green triangles), evolocumab 420 mg QM þ atorvastatin 20 mg (blue stars), evolocumab 140 mg Q2W þ atorvastatin 5 mg
(orange diamonds), and evolocumab 140 mg Q2W þ atorvastatin 20 mg (purple crosses).
Preventive Cardiology/Evolocumab in Japanese Patients 43groups, suggesting good tolerability of both Q2W and QM
dosing regimens. The most common AEs occurring in 2%
of patients in any treatment group are listed in Table 3.
SAEs were infrequent in both groups. One placebo-treated
patient discontinued study drug because of an SAE (brain
stem infarction). Transaminase and creatine kinase eleva-
tions were infrequent (Table 3). Few patients experienced
injection site reactions; all were mild, CTCAE grade 1
(Table 3). One patient treated with evolocumab with a
negative or no result at baseline was found to have an
antievolocumab-binding antibody (Table 3); this patientcompleted the study and had 3 nonserious AEs of upper
respiratory tract infection (twice) and herpes labialis (once);
none was deemed related to evolocumab. No patient re-
ported neurocognitive AEs. Changes at week 12 in fasting
plasma glucose and glycated hemoglobin (HbA1c) were not
notably different in patients receiving evolocumab versus
those receiving placebo (Supplementary Table S1). In
addition, rates of AEs and laboratory abnormalities were
comparable between patients with low LDL-C (<15 mg/dl,
<25 mg/dl or <40 mg/dl; all patients in these groups were
treated with evolocumab) and those with higher LDL-C
Figure 3. LDL-C at screening, baseline, and week 12 according to treatment group.
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Figure 4. Mean % change from baseline versus placebo in other lipids at week 12 in patients receiving evolocumab 140-mg Q2W or 420-mg QM. Numbers in
parenthesis indicate 95% conﬁdence intervals.
44 The American Journal of Cardiology (www.ajconline.org)(40 mg/dl; all placebo patients and 11 patients treated with
evolocumab; Supplementary Table S2).
Discussion
In this study, Japanese patients at high risk for CV dis-
ease according to JAS criteria who were treated with Q2Wor QM evolocumab in combination with background ator-
vastatin showed marked reductions in LDL-C at week 12
compared with patients receiving atorvastatin plus placebo.
These reductions (67% to 76%) fall within the range of
those observed in LAPLACE-2 (55% to 76% vs placebo in
patients treated with 140 mg Q2W or 420 mg QM evolo-
cumab)13 and are also consistent with those observed in
Table 3
Safety
n (%) Atorvastatin þ
Placebo
(N ¼ 202)
Atorvastatin þ
Evolocumab
(N ¼ 202)
Adverse events 103 (51.0%) 94 (46.5%)
Most common adverse events*
Nasopharyngitis 36 (17.8%) 34 (16.8%)
Gastroenteritis 2 (1.0%) 6 (3.0%)
Pharyngitis 5 (2.5%) 5 (2.5%)
Bronchitis 3 (1.5%) 4 (2.0%)
Diabetes mellitus 4 (2.0%)† 4 (2.0%)†
Serious adverse events 5 (2.5%) 1 (0.5%)z
Leading to study drug
discontinuation
1 (0.5%)x 0
Positively adjudicated cardiovascular
events
1 (0.5%)k 0
Creatine kinase > 5 x ULN at any
postbaseline visit
1 (0.5%) 0
ALT or AST > 3 x ULN at any
postbaseline visit
2 (1.0%) 1 (0.5%)
Potential injection-site reactions 5 (2.5%) 5 (2.5%)
Potential muscle events 2 (1%) 1 (0.5%)
Neurocognitive adverse events{ 0 0
Binding antibodies# 0 1 (0.5%)
ALT ¼ alanine aminotransferase; AST ¼ aspartate aminotransferase;
ULN ¼ upper limit of normal.
* Top 5 AEs reported by 2% of patients in any treatment group.
† All 4 patients treated with placebo and 3 patients treated with evolo-
cumab had type 2 diabetes at baseline and reported worsening of pre-
existing diabetes. One patient treated with evolocumab did not have type
2 diabetes at baseline and subsequently developed type 2 diabetes.
z Bacterial pneumonia.
x Brain stem infarction.
k Nonfatal ischemic stroke.
{ Neurocognitive adverse events were self-reported. Searched High
Level Group Terms related to cognitive function were deliria (including
confusion), cognitive and attention disorders and disturbances, dementia
and amnesic conditions, disturbances in thinking and perception, and
mental impairment disorders.
# Postbaseline binding antibody positive, with a negative or no result at
baseline. No neutralizing antibodies were detected.
Preventive Cardiology/Evolocumab in Japanese Patients 45a phase 2 statin combination-therapy study in Japan (64%
and 69% for evolocumab 140 mg Q2W and 420 mg QM,
respectively).7 The range of effect in YUKAWA-2 suggests
modestly greater LDL-C reductions with less variability.
The reasons for this difference is not clear; however, it does
not appear to be explained by factors such as background
statin use, baseline LDL-C or PCSK9 levels, or adherence to
therapy while on study. The response was consistent across
a number of subgroups, including in patients with type 2
diabetes mellitus and patients with metabolic syndrome,
suggesting that evolocumab has a consistent effect in patient
populations at high risk.
At week 12, evolocumab treatment Q2W or QM also
resulted in beneﬁcial changes in other lipids, including re-
ductions in Lp(a) and increases in HDL-C. Lp(a) reductions
(40% to 53% compared with atorvastatin þ placebo) were
greater than those observed in LAPLACE-2 (20% to 36%
compared with control).13 LAPLACE-2 and YUKAWA-2
demonstrated similar baseline Lp(a), LDL-C, and PCSK9levels, but the lower LDL-C levels achieved in YUKAWA-2
could partially explain the greater Lp(a) reduction seen in this
study. The mode of clearance of Lp(a)18 and the mechanism
by which PCSK9 inhibition reduces Lp(a) remain to be fully
elucidated. However, a recent study suggests that plasma
Lp(a) and LDL particles compete for uptake by the LDL re-
ceptor.19 The lower achieved LDL-C levels at week 12
(31 mg/dl in YUKAWA-2 and 44 mg/dl in LAPLACE-2)
would theoretically signal increased LDL receptor availabil-
ity. This, in combination with increased LDL receptor avail-
ability due to PCSK9 inhibition, may partly explain the
greater Lp(a) reduction observed in YUKAWA-2, as there
would be fewer LDL particles to compete with Lp(a), thereby
resulting inmore Lp(a) clearance. This effect, a unique feature
of therapies inhibiting PCSK920 is potentially important as
elevations in Lp(a) are associated with coronary heart disease
risk independent of LDL-C levels.21
Evolocumab also increased HDL-C by 10% to 17%. The
mechanism by which PCSK9 inhibition increases HDL-C is
not known, but one possible explanation is that through
reduction in LDL-C, cholesteryl ester transfer protein activity
is reduced, as a decrease in LDL-C levels would mean less
LDL-C available to receive cholesterol from HDL particles
(thus, indirectly raising the level of HDL-C). At least one
study has shown that changes in HDL-C are associated with
corresponding changes in HDL particle number.22 A direct
increase in ApoA1 or HDL is also possible. An increase in
HDL-C may be therapeutically beneﬁcial as HDLs have been
shown to reduce the risk for CV disease, although questions
remain regarding the use of HDL-C as a biomarker.23
Evolocumab was well tolerated, with no notable imbal-
ances in AEs observed between treatment groups, including
patients achieving very low versus higher LDL-C levels. No
neurocognitive AEs were noted in YUKAWA-2, consistent
with the low incidence observed in other, longer term evo-
locumab studies.24 Roughly half of patients had type 2
diabetes mellitus and a quarter had metabolic syndrome
(with no diabetes) at baseline; despite this, the AE proﬁle for
evolocumab was favorable, with no notable differences in
AEs of diabetes, fasting glucose, or HbA1c between treat-
ment groups.
Statin therapy has been shown inglobal studies to reduce the
incidence of CV events by 20% for every 1-mmol/L reduction
in LDL-C.25 Reduction of LDL-C can reduce CV events
regardless of mechanism.26e29 The recently completed
IMPROVE-IT study, which compared simvastatin plus ezeti-
mibe versus simvastatin alone in >18,000 patients, showed
that LDL-C reduction beyond that provided by statin therapy
further reduces the likelihood of CV events; this effect was not
counterbalanced by safety concerns even with lower achieved
LDL-C levels.27 The potential beneﬁts of nonestatin-mediated
LDL-C reduction are also supported by a recent analysis of
exploratory CV end points in 4,465 patients receiving evolo-
cumab for 1 year, which demonstrated a statistically signiﬁcant
reduction in adjudicated CV events in patients receiving study
drug versus those receiving standard therapy.24 Similar results
have been reported for another PCSK9 inhibitor, alirocumab.30
Thus, PCSK9 inhibition may be an effective tool for reducing
LDL-C in patients at high risk receiving statin therapy who
require additional LDL-C reduction. An ongoing, large, ran-
domized, placebo-controlled study of evolocumab added to
46 The American Journal of Cardiology (www.ajconline.org)effective statin therapy (FOURIER; NCT01764633) will
evaluate the long-term effects of evolocumab treatment on
patient outcomes.
Limitations of this study included the 12-week treatment
duration for the assessment of safety, tolerability, and sus-
tained duration of LDL-C reduction. In addition, this study
incorporated nonintensive (atorvastatin, 5 mg/day) and
intensive (atorvastatin, 20 mg/day) statin use, representative
of standard practice in Japan, which is more conservative
than that in other global regions. This could affect the ability
to compare these results with those of global studies.Acknowledgment: Statistical programming support was
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